Skip to content
MARKETS / NASDAQ / ATRA
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Atara Biotherapeutics, Inc. ATRA

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$120.8M
▼ 6.3% YoY
$32.7M
$-50.9M
In brief

What this company does

Atara Biotherapeutics develops therapies for patients with cancer and autoimmune disease using an allogeneic Epstein-Barr virus (EBV) T-cell platform. Tab-cel (tabelecleucel), marketed under the proprietary name Ebvallo, has received marketing authorization for commercial sale in the European Economic Area, the United Kingdom and Switzerland. The company partnered with Pierre Fabre Medicament for commercialization of tab-cel in Europe. In March 2025, the company decided to pause development of its allogeneic CAR T cell programs and discontinue all CAR T operations for ATA3219 and ATA3431, including terminating the clinical trials evaluating ATA3219. The company has also stopped development on ATA188, an allogeneic T-cell immunotherapy targeting multiple sclerosis. As of December 31, 2025, the company had 14 employees. The company was incorporated in Delaware in 2012.

Written from the business description in Atara Biotherapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 16 March 2026. Every sentence was checked against that document before publication.

Growth
USD 120.8M
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2025 · Revenue 120.8 · Net income 32.7
50M100M-100M-200M2013201520172019202120232025
Compound annual growth
+23.9%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
27 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 29.7% · Net 27.1%
-1000%-2000%-3000%2013201520172019202120232025
ROE
FY2024 · ROE -8768.3%
-5000%2013201520172019202120232025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -50.9
-100M-200M2013201520172019202120232025

Total assetsUSD 20.2M
EquityUSD -38.5M
CashUSD 8.5M
Current ratio0.82×

Equity funds -190% of total assets.

The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B0.10.10.00.1·········
Operating income $B0.0−0.1−0.3−0.3−0.3−0.3−0.3−0.2−0.1−0.1−0.1−0.0−0.0
EBITDA $B0.0−0.1−0.3−0.3·····−0.1−0.1−0.0−0.0
Income tax $B0.0−0.00.00.00.00.00.0−0.0−0.00.0−0.0−0.00.0
Net income $B0.0−0.1−0.3−0.2−0.3−0.3−0.3−0.2−0.1−0.1−0.1−0.0−0.0
Free cash flow $B−0.1−0.1−0.2−0.3−0.2−0.2−0.2−0.2−0.1−0.1−0.0−0.0−0.0
EPS, diluted $2.57−11.41−65.19−2.24−3.63−4.15−5.67−5.27−4.00−2.75···
Dividend / sh $·············
Payout %·············
ROE %·−8768.3−244.5−112.4−91.7−81.4−92.4−89.2−55.4−27.8−27.4−60.8·
Shares out B0.010.010.000.100.090.080.060.050.030.030.030.020.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 50 reconciliationsAUDITED

Reconciled in 14 of 19 fiscal years. 26 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2012

Share this section

Download image